SK158799A3 - Composition comprising finely divided, crystalline particles of budesonide - Google Patents

Composition comprising finely divided, crystalline particles of budesonide Download PDF

Info

Publication number
SK158799A3
SK158799A3 SK1587-99A SK158799A SK158799A3 SK 158799 A3 SK158799 A3 SK 158799A3 SK 158799 A SK158799 A SK 158799A SK 158799 A3 SK158799 A3 SK 158799A3
Authority
SK
Slovakia
Prior art keywords
finely divided
particles
divided particles
budesonide
particles according
Prior art date
Application number
SK1587-99A
Other languages
English (en)
Slovak (sk)
Inventor
Mikael Bisrat
Saeed Moshashaee
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of SK158799A3 publication Critical patent/SK158799A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK1587-99A 1997-05-23 1998-05-15 Composition comprising finely divided, crystalline particles of budesonide SK158799A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9701956A SE9701956D0 (sv) 1997-05-23 1997-05-23 New composition of matter
PCT/SE1998/000908 WO1998052544A1 (en) 1997-05-23 1998-05-15 Composition comprising finely divided, crystalline particles of budesonide

Publications (1)

Publication Number Publication Date
SK158799A3 true SK158799A3 (en) 2000-05-16

Family

ID=20407079

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1587-99A SK158799A3 (en) 1997-05-23 1998-05-15 Composition comprising finely divided, crystalline particles of budesonide

Country Status (28)

Country Link
US (2) US6346523B1 (xx)
EP (1) EP1005328B1 (xx)
JP (1) JP2001525850A (xx)
KR (1) KR100514971B1 (xx)
CN (1) CN1146406C (xx)
AR (1) AR015820A1 (xx)
AT (1) ATE246492T1 (xx)
AU (1) AU734763B2 (xx)
BR (1) BR9808812A (xx)
CA (1) CA2290538C (xx)
DE (1) DE69816997T2 (xx)
DK (1) DK1005328T3 (xx)
EE (1) EE03850B1 (xx)
ES (1) ES2205496T3 (xx)
HU (1) HUP0002212A3 (xx)
ID (1) ID24332A (xx)
IL (1) IL133098A (xx)
IS (1) IS5254A (xx)
NO (1) NO995540D0 (xx)
NZ (1) NZ500852A (xx)
PL (1) PL336902A1 (xx)
PT (1) PT1005328E (xx)
SE (1) SE9701956D0 (xx)
SK (1) SK158799A3 (xx)
TR (1) TR199902880T2 (xx)
TW (1) TW518236B (xx)
WO (1) WO1998052544A1 (xx)
ZA (1) ZA984127B (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE274341T1 (de) * 1995-02-24 2004-09-15 Elan Pharma Int Ltd Nanopartikel-dispersionen enthaltende aerosole
BR0108912A (pt) * 2000-03-03 2002-12-24 Boehringer Ingelheim Pharma Processamento de material por expansão-contração de solvente repetido
CA2433169A1 (en) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Porous substances and methods for producing the same
GB0106403D0 (en) * 2001-03-15 2001-05-02 Pharmaceutical Profiles Labelling of dry powder formulations for inhalation
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
CA2456806C (en) 2001-08-08 2011-10-18 Brown University Research Foundation Methods for micronization of hydrophobic drugs
IL160931A0 (en) * 2001-10-10 2004-08-31 Boehringer Ingelheim Pharma Powder processing with pressurized gaseous fluids
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
WO2004105809A1 (en) 2003-05-22 2004-12-09 Elan Pharma International Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
EP1730751B1 (en) * 2004-03-12 2009-10-21 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A magnetoresistive medium
CN101312713A (zh) * 2005-03-18 2008-11-26 纳米材料科技有限公司 可吸入的药物
WO2007009164A1 (en) 2005-07-15 2007-01-25 Eiffel Technologies Limited Method of particle formation
EP1782839A1 (en) 2005-11-03 2007-05-09 Genetic S.p.A. Sterilization process of Glucocorticosteroid by supercritical CO2
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
EP1988880A2 (en) * 2006-02-15 2008-11-12 Tika Läkemedel AB Stable mixture of corticosteroids
EP2425820B1 (en) 2007-02-11 2015-04-08 MAP Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US20100294986A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Supercritical fluid facilitated particle formation in microfluidic systems
US20100298602A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Systems and methods for microfluidic crystallization
AU2011305567A1 (en) * 2010-09-22 2013-05-02 Map Pharmaceuticals, Inc. Corticosteroid particles and method of production
CN102975731B (zh) * 2012-04-24 2015-08-12 南车南京浦镇车辆有限公司 轨道车辆司机室骨架与车体的安装结构
WO2021219230A1 (en) 2020-04-30 2021-11-04 Paolo Fiorina Antiviral treatment
KR102567655B1 (ko) 2020-11-13 2023-08-17 주식회사 비츠로이엠 진공커패시터 및 진공커패시터 제조 방법
KR20230072023A (ko) 2021-11-17 2023-05-24 주식회사 비츠로이엠 가변형 진공 커패시터의 나선형 전극 위치 결정구조
KR20230072022A (ko) 2021-11-17 2023-05-24 주식회사 비츠로이엠 가변형 진공 커패시터

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282405C (en) 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
EP0437451B1 (en) 1988-10-05 1993-06-09 The Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
JP3282731B2 (ja) 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
CA2356145A1 (en) * 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles

Also Published As

Publication number Publication date
US20020037257A1 (en) 2002-03-28
US6468994B2 (en) 2002-10-22
HUP0002212A2 (hu) 2000-12-28
ZA984127B (en) 1998-11-23
TW518236B (en) 2003-01-21
AR015820A1 (es) 2001-05-30
CA2290538A1 (en) 1998-11-26
NZ500852A (en) 2001-07-27
JP2001525850A (ja) 2001-12-11
DE69816997D1 (de) 2003-09-11
EE9900533A (et) 2000-06-15
CA2290538C (en) 2007-01-02
ATE246492T1 (de) 2003-08-15
WO1998052544A1 (en) 1998-11-26
PL336902A1 (en) 2000-07-17
HUP0002212A3 (en) 2001-04-28
IL133098A (en) 2005-03-20
ID24332A (id) 2000-07-13
US6346523B1 (en) 2002-02-12
IS5254A (is) 1999-11-18
SE9701956D0 (sv) 1997-05-23
DE69816997T2 (de) 2004-07-22
EE03850B1 (et) 2002-10-15
AU7680098A (en) 1998-12-11
AU734763B2 (en) 2001-06-21
CN1257424A (zh) 2000-06-21
PT1005328E (pt) 2003-11-28
ES2205496T3 (es) 2004-05-01
KR100514971B1 (ko) 2005-09-15
NO995540L (no) 1999-11-12
DK1005328T3 (da) 2003-11-17
TR199902880T2 (xx) 2000-02-21
CN1146406C (zh) 2004-04-21
EP1005328B1 (en) 2003-08-06
KR20010012821A (ko) 2001-02-26
NO995540D0 (no) 1999-11-12
IL133098A0 (en) 2001-03-19
EP1005328A1 (en) 2000-06-07
BR9808812A (pt) 2000-07-18

Similar Documents

Publication Publication Date Title
SK158799A3 (en) Composition comprising finely divided, crystalline particles of budesonide
US5983956A (en) Formulation for inhalation
TW492877B (en) Process for the preparation of respirable particles
US6030604A (en) Formulation for inhalation
RU2666963C2 (ru) Агрегированные частицы
JP2010059180A (ja) フォルモテロールを含む０．２８から０．３８ｇ／ｍｌのかさ密度を有する吸入用新規製剤
CA2510263C (en) Preparation of sterile aqueous suspensions comprising micronised crystalline active ingredients for inhalation
CN109793715B (zh) 一种阿哌沙班口服固体制剂及其制备方法
AU728768B2 (en) New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising terbutaline sulphate, a process for preparing the formulation and the use thereof
RU2470639C2 (ru) Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид
US20040247689A1 (en) Process for preparing a pharmaceutical active ingredient with high specific surface area
CN112972384B (zh) 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
SK54593A3 (en) Benzenedimethanol suitable for micronisation
KR20080103614A (ko) 레발부테롤 염
CZ414899A3 (cs) Kompozice obsahující jemně rozptýlené, krystalické částice budesonidu
MXPA99010584A (en) Composition comprising finely divided, crystalline particles of budesonide
WO2021014169A1 (en) Crystalline form of 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-n-cyclohexyl-pyridine-2-carboxamide
WO2021014168A1 (en) Solid forms of 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-n-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide
JP2022139708A (ja) 吸入用乾燥粉末医薬組成物
CN113943283A (zh) 盐酸吡格列酮对氨基苯甲酸共晶及制备和其组合物与用途
SI9200252A (sl) Zdravilni material, primeren za mikronizacijo